

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Initiates Phase 1b Safety Study in Type 2 Diabetes patients

Wilmington, DE – September 10, 2013 – CureDM announces the initiation of a Phase 1b clinical trial in type 2 diabetes patients. This study entitled, “A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β -cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin.” Is designed to incorporate not only safety assessments but also includes key clinical efficacy evaluation to determine efficacy biomarkers.

Primary Outcome Measures include safety and tolerability of repeat doses of HIP2B in subjects with type 2 diabetes mellitus. Secondary outcomes include glucose-stimulated insulin secretion, first-phase insulin response, pre-hepatic insulin secretion rates among other parameters. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications will be pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX